---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000078"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:57:12.818370+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Lipella continued listing with conditions; compliance deadline April 14, 2025

## Summary
- Received Nasdaq Hearings Panel decision on Jan 10, 2025 granting continued listing subject to interim milestones.
- Must file disclosure of equity-increasing transactions and provide fundraising update, income projections by April 14, 2025.
- Must demonstrate compliance with minimum stockholders' equity requirement and plan to meet minimum bid price.
- Company intends to comply but cautions no assurance; failure could lead to delisting.

## SEC filing metadata
- accession: 0001753926-25-000078
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000078/0001753926-25-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000078/g084656_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000078
- JSON: https://secwatch.observer/filing/0001753926-25-000078.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000078.txt

## Source-grounded claims
- claim_id: 08e0e5a5e94c007e19350ee650e0b0ab4ce89366
  claim: LIPELLA PHARMACEUTICALS INC. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1), 5550(a)(2)).
  evidence_excerpt: January 10, 2025, Lipella Pharmaceuticals Inc. (the “Company”) received a decision (the “January Letter”) from the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s requ
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000078/0001753926-25-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.